ONCY Aligns with FDA on Pivotal Anal Cancer Study, Seeks Accelerated Approval, Targets 10K+ US Patients, Pelareorep Shows 15.5 Mo Median Response, 82% 12-Mo Survival
Oncolytics Biotech, Inc. Common Shares · PHARMACEUTICAL PREPARATIONS · Now $1.06
-9.2% in 3d after detection
Post-detection moves
1h
—
1d
-7.1%
3d
-9.2%
7d
-5.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS